Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

FOSTER CITY, Calif., October 19, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights into broader experiences of people living with HIV, as well as emerging antiviral programs.